Cerebral Creatine Deficiency Syndromes

Detalhes bibliográficos
Autor(a) principal: Malheiro, Rui
Data de Publicação: 2013
Outros Autores: Diogo, Luísa, Garcia, Paula, Fineza, Isabel, Oliveira, Guiomar
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355
Resumo: Introduction: Creatine deficiency syndromes are a recently described group of diseases characterized by inborn errors of creatinemetabolism. Clinical features include a spectrum of neurodevelopment disorders of diverse severity. They are characterized by lowlevels of cerebral creatine caused by different pathogenic mutations concerning the genes coding for creatine synthesis enzymes[arginine: glicyne amidinotransferase (AGAT, EC 2.1.4.1) and guanidinoacetate methyltansferase (GAMT, EC 2.1.1.2)], AGAT andGAMT, respectively, or its transporter (CT1 deficiency), SLC6A8. Enzymatic deficiencies are transmitted as autosomal recessive traits,whereas the transporter deficit is X-linked.Objectives: To characterize the clinical and laboratorial presentation, diagnosis and treatment of cerebral creatine deficiency patients,followed in Hospital Pediátrico Carmona da Mota. The awareness of these inborn errors of metabolism as neurological disorders,namely of neurodevelopment, among the medical community is a secondary aim of the present work.Methods and Material: Retrospective analysis of the clinical files of patients followed in our Hospital and diagnosed with cerebralcreatine deficiency syndrome.Results: Twelve patients belonging to seven different families were diagnosed with creatine deficiency syndromes. Five presentedGAMT deficiency and seven CT1 deficiency. Present ages are 2 to 38 years old. The most common clinical presentations were: globaldevelopment delay in seven patients (two with epilepsy), and speech delay in two patients. Only one patient had communication andsocial interaction dysfunction. In all, global development delay in the range of intellectual delay was identified. The pathognomonic patternof cerebral creatine deficiency in the brain image was demonstrated in eight patients. Pathogenic mutations in GAMT or SLC6A8genes were identified in all cases.Conclusions: The suspicion of cerebral creatine depletion must be considered in all children presenting unexplained global psychomotordevelopment delay. Pre-symptomatic therapy has shown promising results, especially in GAMT deficiency patients. The high rate ofasymptomatic carriers of GAMT mutations in our population makes this disorder eligible to neonatal screening in Portugal.
id RCAP_5cbffc111fcec6c24c2d9de7c810894f
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/1355
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Cerebral Creatine Deficiency SyndromesSíndromes de Deficiência Cerebral de CreatinaIntroduction: Creatine deficiency syndromes are a recently described group of diseases characterized by inborn errors of creatinemetabolism. Clinical features include a spectrum of neurodevelopment disorders of diverse severity. They are characterized by lowlevels of cerebral creatine caused by different pathogenic mutations concerning the genes coding for creatine synthesis enzymes[arginine: glicyne amidinotransferase (AGAT, EC 2.1.4.1) and guanidinoacetate methyltansferase (GAMT, EC 2.1.1.2)], AGAT andGAMT, respectively, or its transporter (CT1 deficiency), SLC6A8. Enzymatic deficiencies are transmitted as autosomal recessive traits,whereas the transporter deficit is X-linked.Objectives: To characterize the clinical and laboratorial presentation, diagnosis and treatment of cerebral creatine deficiency patients,followed in Hospital Pediátrico Carmona da Mota. The awareness of these inborn errors of metabolism as neurological disorders,namely of neurodevelopment, among the medical community is a secondary aim of the present work.Methods and Material: Retrospective analysis of the clinical files of patients followed in our Hospital and diagnosed with cerebralcreatine deficiency syndrome.Results: Twelve patients belonging to seven different families were diagnosed with creatine deficiency syndromes. Five presentedGAMT deficiency and seven CT1 deficiency. Present ages are 2 to 38 years old. The most common clinical presentations were: globaldevelopment delay in seven patients (two with epilepsy), and speech delay in two patients. Only one patient had communication andsocial interaction dysfunction. In all, global development delay in the range of intellectual delay was identified. The pathognomonic patternof cerebral creatine deficiency in the brain image was demonstrated in eight patients. Pathogenic mutations in GAMT or SLC6A8genes were identified in all cases.Conclusions: The suspicion of cerebral creatine depletion must be considered in all children presenting unexplained global psychomotordevelopment delay. Pre-symptomatic therapy has shown promising results, especially in GAMT deficiency patients. The high rate ofasymptomatic carriers of GAMT mutations in our population makes this disorder eligible to neonatal screening in Portugal.Introdução: As síndromes de deficiência cerebral de creatina (OMIM 300036) são um grupo de patologias recentemente descritas,caracterizadas por defeitos congénitos no metabolismo da creatina. A apresentação clínica compreende um espectro variado deperturbações do neurodesenvolvimento. Os baixos níveis de creatina cerebral verificados nestes doentes devem-se a diferentesmutações nos genes que codificam as enzimas de síntese da creatina [arginina:glicina amidinotransferase (AGAT, EC 2.1.4.1), emetiltransferase do ácido guanidinoacético (GAMT, EC 2.1.1.2)], AGAT e GAMT, respectivamente, ambas de transmissão autossómicarecessiva, ou o seu transportador (CT1), SLC6A8, de transmissão ligada ao cromossoma X.Objectivo: Caracterizar o espectro de apresentação clínica e laboratorial dos doentes com o diagnóstico da síndrome de deficiênciade creatina cerebral seguidos no Hospital Pediátrico Carmona da Mota, bem como a sua orientação diagnóstica e terapêutica. Adivulgação destes erros inatos do metabolismo enquanto doenças neurológicas, nomeadamente do neurodesenvolvimento, entre acomunidade médica é outro dos propósitos almejados.Material e Métodos: Análise retrospectiva dos processos clínicos de doentes com o diagnóstico de deficiência cerebral da creatinaseguidos no Hospital Pediátrico.Resultados: Foram identificados doze doentes com défice cerebral da creatina pertencentes a sete famílias. Cinco apresentam deficiênciade metiltransferase do ácido guanidinoacético e sete do transportador de creatina. Têm actualmente entre dois e 38 anos.Os principais motivos de consulta foram: atraso global de desenvolvimento em sete doentes, dois dos quais também apresentavamepilepsia, e atraso da linguagem em outros dois. Apenas num caso o motivo de consulta foi défice de interacção social e de comunicação.Em todos os casos se registou um quociente de desenvolvimento global na faixa da deficiência intelectual. O estudo imagiológicodemonstrou o padrão patognomónico destas síndromes em oito doentes. No estudo genético foram identificadas mutações nos genesGAMT ou SLC6A8 nos doze casos.Conclusões: A suspeita de deficiência de creatina cerebral deve ser considerada em todos os casos de atraso de desenvolvimentopsicomotor sem outra causa evidente. A terapêutica pré-sintomática tem mostrado resultados promissores em algumas crianças comdéfice cerebral de creatina, sobretudo nos défices de GAMT. A elevada taxa de portadores de mutações do gene GAMT em Portugaltorna esta anomalia elegível para o rastreio neonatal no nosso País.Ordem dos Médicos2013-01-28info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355oai:ojs.www.actamedicaportuguesa.com:article/1355Acta Médica Portuguesa; Vol. 25 No. 6 (2012): November-December; 389-398Acta Médica Portuguesa; Vol. 25 N.º 6 (2012): Novembro-Dezembro; 389-3981646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355/948Malheiro, RuiDiogo, LuísaGarcia, PaulaFineza, IsabelOliveira, Guiomarinfo:eu-repo/semantics/openAccess2022-12-20T10:57:46Zoai:ojs.www.actamedicaportuguesa.com:article/1355Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:17:05.191503Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Cerebral Creatine Deficiency Syndromes
Síndromes de Deficiência Cerebral de Creatina
title Cerebral Creatine Deficiency Syndromes
spellingShingle Cerebral Creatine Deficiency Syndromes
Malheiro, Rui
title_short Cerebral Creatine Deficiency Syndromes
title_full Cerebral Creatine Deficiency Syndromes
title_fullStr Cerebral Creatine Deficiency Syndromes
title_full_unstemmed Cerebral Creatine Deficiency Syndromes
title_sort Cerebral Creatine Deficiency Syndromes
author Malheiro, Rui
author_facet Malheiro, Rui
Diogo, Luísa
Garcia, Paula
Fineza, Isabel
Oliveira, Guiomar
author_role author
author2 Diogo, Luísa
Garcia, Paula
Fineza, Isabel
Oliveira, Guiomar
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Malheiro, Rui
Diogo, Luísa
Garcia, Paula
Fineza, Isabel
Oliveira, Guiomar
description Introduction: Creatine deficiency syndromes are a recently described group of diseases characterized by inborn errors of creatinemetabolism. Clinical features include a spectrum of neurodevelopment disorders of diverse severity. They are characterized by lowlevels of cerebral creatine caused by different pathogenic mutations concerning the genes coding for creatine synthesis enzymes[arginine: glicyne amidinotransferase (AGAT, EC 2.1.4.1) and guanidinoacetate methyltansferase (GAMT, EC 2.1.1.2)], AGAT andGAMT, respectively, or its transporter (CT1 deficiency), SLC6A8. Enzymatic deficiencies are transmitted as autosomal recessive traits,whereas the transporter deficit is X-linked.Objectives: To characterize the clinical and laboratorial presentation, diagnosis and treatment of cerebral creatine deficiency patients,followed in Hospital Pediátrico Carmona da Mota. The awareness of these inborn errors of metabolism as neurological disorders,namely of neurodevelopment, among the medical community is a secondary aim of the present work.Methods and Material: Retrospective analysis of the clinical files of patients followed in our Hospital and diagnosed with cerebralcreatine deficiency syndrome.Results: Twelve patients belonging to seven different families were diagnosed with creatine deficiency syndromes. Five presentedGAMT deficiency and seven CT1 deficiency. Present ages are 2 to 38 years old. The most common clinical presentations were: globaldevelopment delay in seven patients (two with epilepsy), and speech delay in two patients. Only one patient had communication andsocial interaction dysfunction. In all, global development delay in the range of intellectual delay was identified. The pathognomonic patternof cerebral creatine deficiency in the brain image was demonstrated in eight patients. Pathogenic mutations in GAMT or SLC6A8genes were identified in all cases.Conclusions: The suspicion of cerebral creatine depletion must be considered in all children presenting unexplained global psychomotordevelopment delay. Pre-symptomatic therapy has shown promising results, especially in GAMT deficiency patients. The high rate ofasymptomatic carriers of GAMT mutations in our population makes this disorder eligible to neonatal screening in Portugal.
publishDate 2013
dc.date.none.fl_str_mv 2013-01-28
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355
oai:ojs.www.actamedicaportuguesa.com:article/1355
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/1355
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1355/948
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 25 No. 6 (2012): November-December; 389-398
Acta Médica Portuguesa; Vol. 25 N.º 6 (2012): Novembro-Dezembro; 389-398
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130624525598720